Table 2.
Caucasian | Hispanic | African American | All | |||||
---|---|---|---|---|---|---|---|---|
Control | MS | Control | MS | Control | MS | Control | MS | |
Number of samples | 9 | 9 | 8 | 8 | 7 | 7 | 24 | 24 |
Age [years; mean ± SD (range)] | 30.3 ± 10.2 (22–55) | 42.0 ± 12.6 (22–59)* | 33.1 ± 8.1 (20–44) | 31.6 ± 9.6 (19–50) | 37.8 ± 11.9 (27–58) | 36.4 ± 12.4 (23–54) | 33.5 ± 10.1 (22–55) | 36.9 ± 12.0 (22–58) |
% Female | 67 | 78 | 50 | 75 | 71 | 71 | 63 | 75 |
All MS subjects selected for these analyses were treatment-naïve, were diagnosed within 6 months of the specimen collection, had symptom onset within the prior year, and did not receive steroids in the prior month. The MS CA subjects were significantly (*p = 0.05) older than the Control CA subjects; there were no significant differences in the other pairwise comparisons by age or sex.